Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman Sells 60,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 60,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $55.66, for a total value of $3,339,600.00. Following the completion of the transaction, the director now owns 441,233 shares in the company, valued at approximately $24,559,028.78. The trade was a 11.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

William Hoffman also recently made the following trade(s):

• On Monday, November 18th, William Hoffman sold 60,000 shares of Inari Medical stock. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00.
• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $50.05, for a total transaction of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00.

Inari Medical Stock Performance

Shares of NASDAQ NARI opened at $55.03 on Thursday. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $67.10. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of -40.76 and a beta of 0.97. The company has a 50 day simple moving average of $49.30 and a two-hundred day simple moving average of $48.04.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Truist Financial raised their target price on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday. Robert W. Baird raised their price target on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Leerink Partnrs upgraded Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. Finally, Oppenheimer began coverage on shares of Inari Medical in a research report on Tuesday. They set an “outperform” rating and a $75.00 price target on the stock. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Inari Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.80.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jennison Associates LLC lifted its position in Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock valued at $65,021,000 after acquiring an additional 610,468 shares in the last quarter. Vestal Point Capital LP lifted its holdings in shares of Inari Medical by 342.9% during the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after purchasing an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Inari Medical by 113.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock worth $71,324,000 after buying an additional 786,691 shares in the last quarter. Armistice Capital LLC raised its position in Inari Medical by 353.1% in the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock worth $48,595,000 after buying an additional 786,501 shares during the last quarter. Finally, Bamco Inc. NY lifted its stake in Inari Medical by 29.5% during the 3rd quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock valued at $41,493,000 after acquiring an additional 228,977 shares during the period. Institutional investors own 90.98% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.